Medicare Advantage (Part C) vs Medicare Supplement + Part D: Out-of-Pocket Max & Drug Formularies
Bundled managed care MOOP caps versus unbundled Medigap statutory coverage and standalone PDP tiers
Medicare Advantage (Part C) bundles hospital (Part A), medical (Part B), and prescription drug coverage into private HMO/PPO plans with statutory Maximum Out-of-Pocket (MOOP) limits ($8,850 in 2026) in exchange for restricted provider networks and prior authorization rules. Original Medicare coupled with a Medigap policy (e.g. Plan G) and a standalone Part D Prescription Drug Plan (PDP) provides unrestricted nationwide physician access and eliminates copays, carrying a fixed monthly premium structure.
Technical Tradeoff & Benchmark Matrix
| Program Attribute | Medicare Advantage (Part C HMO/PPO) | Medigap Plan G + Standalone Part D |
|---|---|---|
| Network Architecture | Restricted HMO/PPO network; out-of-network care penalized or denied | Any doctor or hospital in the US that accepts Medicare (no network walls) |
| Prior Authorization Burden | Required for specialist referrals, MRI/CT imaging, chemotherapy, and surgery | Zero prior authorizations; coverage is automatic if service is Medicare-approved |
| Out-of-Pocket Protection | Mandatory in-network MOOP cap (statutory maximum $8,850 in 2026) | Plan G covers 100% of out-of-pocket costs after small Part B deductible ($240) |
| Prescription Drug Delivery | Integrated Part D benefit (MAPD); formulary changes annually | Requires purchasing a separate standalone Prescription Drug Plan (PDP) |
| Monthly Premium Structure | Low to $0 monthly plan premium (funded via CMS risk capitation) | Substantial monthly premium ($150-$250 for Plan G + $20-$80 for Part D) |
| International Emergency Travel | Limited emergency travel benefit or none | Covers 80% of foreign travel emergency care up to $50,000 lifetime limit |
Interactive Calculation Engines
Calculate empirical values directly using our zero-latency edge computational models:
Frequently Asked Questions & Technical Analysis
Q: What happens if a Medicare Advantage enrollee develops a complex oncology diagnosis?
Under Medicare Advantage, cancer treatments require prior authorization from the private insurer, and care is restricted to in-network oncologists and medical centers. Patients desiring specialized cancer institutes (e.g. MD Anderson, Memorial Sloan Kettering) must obtain out-of-network approval or face substantial out-of-pocket bills.
Q: How does the Inflation Reduction Act impact Part D drug out-of-pocket caps in 2026?
Starting in 2025-2026, the Inflation Reduction Act completely eliminates the 'donut hole' coverage gap, placing a hard $2,000 statutory cap on annual out-of-pocket prescription drug spending across all Part D plans.